Company news

ImmuneOnco won the project supported by Science and Technology Commission of Shanghai Municipality

2019-6-5 0:00:00Click:356

       On June 4, 2019, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was awarded by Shanghai science and technology achievements transformation and industrialization project 2019. The project number is 19431907100. The project is a phase I clinical study of rhSIRPaD1-Fc, a novel immunoregulatory target drug.

   This project activates macrophages by blocking the interaction of CD47-SIRPa, so that the latter can phagocytize tumor cells and present the phagocytosis-treated tumor antigens to T cells, thus exerting a powerful immunotherapeutic effect on tumors. Pre-clinical studies have proved that it has remarkable therapeutic effect and good safety.

   ImmuneOnco has acquired all the intellectual property rights of the project through independent research and development.